Paractin and Rheumatoid Arthritis (RA)
Address: 707 24th Ave W
Bradenton, FL 34205
Toll Free Tel: (877) 437-2234
Toll Free Fax: (866) 278-2874
Email: info@hpinsm:dients.com
Web Site: www.hpingredients.com
ParActin® Research Summary
Clin Rheumatol (2009) 28:931-946
DO I 10.1007/s 10067-009-1180-5
ORIGINAL ARTICLE
Efficacy of an Andrographis paniculata composition
for the relief of rheumatoid arthritis symptoms:
a prospective randomized placebo-controlled trial
R. A. Burgos 'J. L. Han eke • J. C. Bertoglio •
V- Aguirre ♦ S. Arrlagada • M. Calvo • I>. 1). C^ceres
A randomized, double blind, and placebo-controlled study in patients with
rheumatoid arthritis (RA) was performed. lOOmg of Paractin® were administered three times a day for 14
weeks, after a 2-week washout period to 60 patients with active RA. Patients were allowed to take
prednisone or chloroquine (stable doses). MTX was administered to all patients as standard treatment.
On day 1, and at the end of week 2, week 6, week 10, and week 14 the following exams were
performed:
1. Evaluation of the number of inflammatory and painful joints.
2. Evaluation of pain by the patient utilizing the Visual Analog Scale (VAS).
3. Improvement in the evaluation of health quality of life questionnaires
4. Duration of morning rigidity.
5. Global evaluation of symptoms by the patient and researchers.
6. Global evaluation of the tolerance by the patient and researchers.
Paractin® Group showed significant diminishing in:
1. number of swollen joints (Paractin 9 vs Placebo 13)
2. total grade of swollen joint (Paractin 11 vs Placebo 16)
3. total grade of tender joints (Paractin 14 vs Placebo 17)
4. HAQ (Paractin 19 vs Placebo 24)
5. reduction of rheumatoid factor (Paractin 119 vs Placebo 130)
6. reduction in IgA (Paractin 293.7 vs placebo 335)